Valicenti Advisory Services’s Anika Therapeutics ANIK Stock Holding History

Valicenti Advisory Services’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-34,675	Closed	-$1.32M	–	50
2015 Q4	$1.32M	Sell	34,675 -2,875	-8%	-$110K	0.89%	31
2015 Q3	$1.2M	Sell	37,550 -2,550	-6%	-$88.9K	0.79%	38
2015 Q2	$1.32M	Sell	40,100 -150	-0.4%	-$5.35K	0.85%	40
2015 Q1	$1.66M	Sell	40,250 -1,300	-3%	-$52.6K	1.04%	39
2014 Q4	$1.69M	Buy	41,550 +150	+0.4%	+$5.86K	1.01%	37
2014 Q3	$1.52M	Buy	+41,400	New	+$1.79M	0.93%	39

Other funds holding ANIK

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

AAM

AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Valicenti Advisory Services's ANIK Position: Q1 2016 in Review

Valicenti Advisory Services sold out of Anika Therapeutics (ANIK) in Q1 2016, closing a stake of 34,675 shares — an estimated $1.32M sold.

Valicenti Advisory Services first reported a position in ANIK in Q3 2014 and held it in 6 quarters. The position peaked at $1.69M in Q4 2014. 162 funds tracked by Wall St. Rank hold ANIK as of Q1 2016.

Valicenti Advisory Services reported no remaining Anika Therapeutics position as of Q1 2016 after selling out during the quarter.
Valicenti Advisory Services sold 34,675 Anika Therapeutics shares in Q1 2016, an estimated $1.32M.
Valicenti Advisory Services first reported a position in Anika Therapeutics in Q3 2014 and held it in 6 quarters.
Valicenti Advisory Services's Anika Therapeutics position peaked at $1.69M in Q4 2014.
162 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2016.

Based on Valicenti Advisory Services's 13F filing for Q1 2016, filed 26 Apr 2016.